<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01660737</url>
  </required_header>
  <id_info>
    <org_study_id>180A12PALL</org_study_id>
    <nct_id>NCT01660737</nct_id>
  </id_info>
  <brief_title>Observational Study With PASCALLERG ® in Patients With Hay Fever</brief_title>
  <official_title>Observational Study With PASCALLERG ® in Patients With Hay Fever</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pascoe Pharmazeutische Praeparate GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pascoe Pharmazeutische Praeparate GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this observational study is to document the therapeutic use of PASCALLERG ® for
      hay fever. Based on the survey is a decrease in disease-specific symptoms when taking
      PASCALLERG ® over a period of 4 weeks will be documented. In addition to the compatibility
      can be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are documented male and female patients over the age of one year who suffer from hay
      fever. The traetment time is about a period of 4 weeks with PASCALLERG® tablets.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Pascallerg</measure>
    <time_frame>appr. 4 weeks after baseline (after appr. 4 weeks of treatment)</time_frame>
    <description>Request of Efficacy using a 4-stage scale (very good efficacy, good efficacy, moderate efficacy, no efficacy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>app. 4 weeks after baseline (treatment app. for 4 weeks)</time_frame>
    <description>Request of Tolerability using a 2-stage scale (very good tolerability, bad tolerability)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale Well Beeing (Pre- Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
    <description>Influence of allergy on the general well-being (scale from 0-no influence to 10 strong influence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Dry Eyes (Pre- Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Itching Eyes (Pre- Post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Burning Eyes (Pre-post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Bronchial Complaints (Pre-post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Sneezing (Pre-post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Rhinitis (Pre-post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symtom Fatigue / Tiredness</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Headache (Pre-post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Symptom Tearing Eyes (Pre-post)</measure>
    <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
    <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">123</enrollment>
  <condition>Hay Fever</condition>
  <arm_group>
    <arm_group_label>PASCALLERG® tablets in patients with hay fever</arm_group_label>
    <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients from natural practioners and doctors from Germany
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hay fever

        Exclusion Criteria:

          -  Lactose intolerance and / or

          -  Chromium hypersensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jennifer Lebert</name>
      <address>
        <city>Gießen</city>
        <zip>35390</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2012</study_first_submitted>
  <study_first_submitted_qc>August 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2012</study_first_posted>
  <results_first_submitted>April 21, 2016</results_first_submitted>
  <results_first_submitted_qc>April 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2017</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hay fever</keyword>
  <keyword>Pascallerg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
          <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
          <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.00" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Pascallerg</title>
        <description>Request of Efficacy using a 4-stage scale (very good efficacy, good efficacy, moderate efficacy, no efficacy)</description>
        <time_frame>appr. 4 weeks after baseline (after appr. 4 weeks of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Pascallerg</title>
          <description>Request of Efficacy using a 4-stage scale (very good efficacy, good efficacy, moderate efficacy, no efficacy)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very good efficacy (symptoms complete decline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good efficacy (symptoms clearly improved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate efficacy (smptoms slightly improved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No efficacy (symptoms unchanged o worsend)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability</title>
        <description>Request of Tolerability using a 2-stage scale (very good tolerability, bad tolerability)</description>
        <time_frame>app. 4 weeks after baseline (treatment app. for 4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability</title>
          <description>Request of Tolerability using a 2-stage scale (very good tolerability, bad tolerability)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad tolerability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numerical Rating Scale Well Beeing (Pre- Post)</title>
        <description>Influence of allergy on the general well-being (scale from 0-no influence to 10 strong influence)</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Rating Scale Well Beeing (Pre- Post)</title>
          <description>Influence of allergy on the general well-being (scale from 0-no influence to 10 strong influence)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>detoriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Dry Eyes (Pre- Post)</title>
        <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Dry Eyes (Pre- Post)</title>
          <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Itching Eyes (Pre- Post)</title>
        <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Itching Eyes (Pre- Post)</title>
          <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Burning Eyes (Pre-post)</title>
        <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Burning Eyes (Pre-post)</title>
          <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Bronchial Complaints (Pre-post)</title>
        <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Bronchial Complaints (Pre-post)</title>
          <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deterioreated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Sneezing (Pre-post)</title>
        <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Sneezing (Pre-post)</title>
          <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Rhinitis (Pre-post)</title>
        <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Rhinitis (Pre-post)</title>
          <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symtom Fatigue / Tiredness</title>
        <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symtom Fatigue / Tiredness</title>
          <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Headache (Pre-post)</title>
        <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Headache (Pre-post)</title>
          <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Symptom Tearing Eyes (Pre-post)</title>
        <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
        <time_frame>Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 4 weeks after baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
            <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Symptom Tearing Eyes (Pre-post)</title>
          <description>Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PASCALLERG® Tablets in Patients With Hay Fever</title>
          <description>Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Lebert</name_or_title>
      <organization>PASCOE Pharamzeutische Präparate GmbH</organization>
      <phone>0049+(0)641-7960-955</phone>
      <email>Jennifer.lebert@pascoe.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

